Skip to main
KLRS

Allovir Inc (KLRS) Stock Forecast & Price Target

Allovir Inc (KLRS) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kalaris Therapeutics is well-positioned in the lucrative anti-VEGF market with their promising treatment option, TH103, and potential for a differentiated and safer profile than their main competitor. Ongoing studies and a new manufacturing batch are expected to support the continued success of TH103, but potential delays in development and approval must also be considered in the overall outlook. As a clinical-stage biopharmaceutical company, Kalaris' strong financials and ability to secure funding demonstrate their dedication to bringing TH103 to market, making it a strong investment opportunity with the potential for long-term growth.

Bears say

Kalaris Therapeutics is a company with a promising new treatment for wet AMD, showing better results than current standard of care, and a strong financial position. However, potential risks in regulatory and commercial aspects, along with the need for effective marketing, could impact the success of their pipeline and their ability to reach the current price target of $19. As a result, it is important to closely monitor their progress and the potential challenges they may face.

Allovir Inc (KLRS) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allovir Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allovir Inc (KLRS) Forecast

Analysts have given Allovir Inc (KLRS) a Buy based on their latest research and market trends.

According to 5 analysts, Allovir Inc (KLRS) has a Buy consensus rating as of Jun 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allovir Inc (KLRS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.